^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SEMA7A expression

    i
    Other names: Semaphorin 7A (John Milton Hagen Blood Group), Sema Domain, Immunoglobulin Domain (Ig), And GPI Membrane Anchor, (Semaphorin) 7A (JMH Blood Group), Semaphorin 7A, GPI Membrane Anchor (John Milton Hagen Blood Group), John-Milton-Hargen Human Blood Group Ag, JMH Blood Group Antigen, Semaphorin-7A, Semaphorin-K1, Semaphorin-L, Sema K1, Sema L, CDw108, SEMAL, CD108, Sema Domain, Immunoglobulin Domain (Ig), And GPI Membrane Anchor, (Semaphorin) 7A, Sema Domain, Immunoglobulin Domain (Ig), And GPI Mem
    Entrez ID:
    8482
    Related biomarkers:
    Expression
    1year
    SEMA7A-mediated juxtacrine stimulation of IGFBP-3 upregulates IL-17RB at pancreatic cancer invasive front. (PubMed, Cancer Gene Ther)
    The resulting gradient of IGFBP-3 influences the direction and enhances IL-17RB expression to regulate SNAI2 in invasion. These findings highlight the importance of local tumor-fibroblast interactions in promoting cancer cell invasiveness, potentially leading to the development of new therapeutic strategies targeting this communication.
    Journal
    |
    SEMA7A (Semaphorin 7A) • IGFBP3 (Insulin-like growth factor binding protein 3) • SNAI2 (Snail Family Transcriptional Repressor 2) • ATP1A1 (ATPase Na+/K+ Transporting Subunit Alpha 1) • IL17RB (Interleukin 17 Receptor B)
    |
    SEMA7A expression • IL17RB expression
    1year
    Associations of SEMA7A, SEMA4D, ADAMTS10, and ADAM8 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations, Microsatellite Instability Status, and Cytokine Expression in Colorectal Cancer Tissue. (PubMed, Curr Issues Mol Biol)
    The SEMA7A and SEMA4D expressions were correlated with the expression of numerous cytokines associated with various immune processes. The potential immunomodulatory functions of these molecules and their suitability as therapeutic targets require further investigation.
    Journal • Microsatellite instability
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • SEMA7A (Semaphorin 7A) • ADAM8 (ADAM Metallopeptidase Domain 8) • SEMA4D (Semaphorin 4D)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • PIK3CA mutation • ADAMTS1 expression • SEMA7A expression
    1year
    SEMA7A as a Novel Prognostic Biomarker and Its Correlation with Immune Infiltrates in Breast Cancer. (PubMed, Int J Gen Med)
    The efficiency of SEMA7A as a reliable prognostic biomarker for BC has been substantiated by the validation of ROC curves and nomograms. SEMA7A has the potential to function as a prognostic indicator for BC, and its correlation with immune infiltration in BC is significant.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • SEMA7A (Semaphorin 7A)
    |
    SEMA7A expression
    almost3years
    The effect of Semaphorin 7A on breast cancer metastases and chemoresistance in young women (AACR 2023)
    EMP is also known to promote chemoresistance and we have found that SEMA7A OE cells are resistant to caspase-mediated cell death in the presence of paclitaxel, a known chemotherapeutic utilized for TNBC, and have increased activation of pAkt, which can mediate pro-survival phenotypes. Overall, our results suggest that the aged mammary gland and SEMA7A expression can promote metastatic spread and chemoresistance and that these patient populations should be considered for direct and indirect targeting of SEMA7A by novel therapeutics.
    Clinical
    |
    SEMA7A (Semaphorin 7A)
    |
    SEMA7A expression
    |
    paclitaxel
    almost3years
    Semaphorin 7A interacts with nuclear factor NF-kappa-B p105 via integrin β1 and mediates inflammation. (PubMed, Cell Commun Signal)
    In conclusion, our findings suggest that the Sema7a (SEMA7A) mutation and high Sema7a (SEMA7A) expression both activate the NF-κB p50/p65 pathway via integrin β1 and play a crucial role in inflammatory responses. Video Abstract.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • SEMA7A (Semaphorin 7A) • IL1B (Interleukin 1, beta)
    |
    SEMA7A overexpression • SEMA7A expression
    over3years
    A Comprehensive Prognostic Analysis of Tumor-Related Blood Group Antigens in Pan-Cancers Suggests That SEMA7A as a Novel Biomarker in Kidney Renal Clear Cell Carcinoma. (PubMed, Int J Mol Sci)
    In conclusion, our analysis indicates that blood group antigens may play functional important roles in tumorigenesis, progression, and especially prognosis. These results provide data to support prognostic marker development and future clinical management.
    Journal • Pan tumor
    |
    CD44 (CD44 Molecule) • SEMA7A (Semaphorin 7A) • AQP1 (Aquaporin 1) • FUT7 (Fucosyltransferase 7)
    |
    SEMA7A expression
    4years
    Semaphorin7a expression in breast cancers promotes susceptibility to immune checkpoint blockade (SABCS 2021)
    Semaphorin 7A Promotes Macrophage-Mediated Lymphatic Remodeling during Postpartum Mammary Gland Involution and in Breast Cancer. Cancer research 78 , 6473-6485 (2018).
    Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • SEMA7A (Semaphorin 7A)
    |
    PD-L1 expression • SEMA7A overexpression • SEMA7A expression
    4years
    Anoikis resistance in mammary epithelial cells is mediated by semaphorin 7a. (PubMed, Cell Death Dis)
    Our results reveal that SEMA7A is expressed on live mammary epithelial cells during involution, that SEMA7A expression is primarily observed in α6-integrin expressing cells, and that luminal progenitor cells, specifically, are decreased in mammary glands of SEMA7A-/- mice during involution. We further identify a SEMA7A-α6/β1-integrin dependent mechanism of mammosphere formation and chemoresistance in mammary epithelial cells and suggest that this mechanism is relevant for recurrence in breast cancer patients.
    Journal
    |
    SEMA7A (Semaphorin 7A)
    |
    SEMA7A expression